论文部分内容阅读
当前,医药行业的竞争日趋激烈,兼并与重组的浪潮一浪高过一浪。随着国家新医改政策的深入推进,医药行业将面临着新一轮的洗牌,制药企业的竞争格局将发生深刻变化,行业的集中度会越来越高,竞争优势会逐步向品牌影响力大、产品竞争力强、商业信誉好的大企业倾斜。在未来5至10年间前20名企业的市场份额将达到50%以上,中小企业独立生存的空间将越来越小,生存处境将越来越艰难。“不谋全局者,不足以谋一域;不谋万世者,不足以谋一时。”佛慈制药的未来10年,将在成功上市之后,抢抓机遇,加快发展,使公司跻身全国中成药制药企业前10名,品牌影响力进入前5强。
At present, the competition in the pharmaceutical industry is becoming more and more intense. The wave of mergers and acquisitions has been wave after wave. With the deepening of the national new medical reform policy, the pharmaceutical industry will face a new round of reshuffling. The competitive landscape of pharmaceutical companies will undergo profound changes. The concentration of the industry will be higher and higher, and its competitive edge will gradually affect the brand Large, strong product competitiveness, good business reputation of large enterprises tilt. In the next 5 to 10 years, the market share of the top 20 enterprises will reach over 50%. The space for SMEs to survive independently will become smaller and smaller, and their living conditions will become more and more difficult. “Do not seek the overall situation, not enough to seek a domain; do not make the worldly, not enough time to seek.” "Buddha Ci Pharmaceutical’s next 10 years, after the successful listing, seize the opportunity to accelerate the development of the company among the nation Top 10 pharmaceutical companies in proprietary Chinese medicine, brand influence into the top 5.